Best Read Articles on Biosimilars in 2021

News about interchangeable Semglee (insulin glargine-yfgn) was among the most read in 2021.

Prime Therapeutics Adds the Biosimilar Semglee to Preferred Formulary


Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.

Read more

OptumRx Excludes the Diabetes Biosimilar Semglee from Formulary


OptumRx will favor the reference product Lantus on the Premium Formulary. The organization also released coverage information about other newly approved therapies.

Read more

Survey: Biosimilars are Gaining Momentum Among Payers

AmerisourceBergen/Xcenda survey finds payers believe biosimilars provide costs savings, and they are expected to continuing contracting with manufacturers.


Read more

Walgreens Offering Biosimilar and Interchangeable Insulin Semglee


Patients who are part of the Walgreen’s Prescription Savings Club can receive Semglee at up to 80% off the cash price.


Read more

Study: Medicare Part B Reimbursement Hinders Biosimilar Uptake

A reimbursement policy similar to that used for branded and generic drugs would have saved $1.6 billion from 2015 to 2019.

Read more